このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Co-development of a Deprescribing Program for Older Community-dwelling Patients Treated With Anticholinergic/Sedative Medications (CC-DIOPAS)

2026年6月25日 更新者:Hospices Civils de Lyon

Co-development of a Multidisciplinary, Participatory Deprescribing Program for Older Community-dwelling Patients Treated by Medications With Anticholinergic and/or Sedative Properties

About 20% of emergency room admissions among people over the age of 75 are related to medication-induced adverse events. These events are exacerbated by polypharmacy, which can be inappropriate when prescribed medications have an uncertain benefit-risk balance or cause harmful drug interactions. Among potentially inappropriate medications (PIMs), those with anticholinergic and/or sedative properties are the most harmful to older adults and yet are very frequently prescribed. Indeed, in France, 33% of older patients living at home are treated with this type of medication, the use of which is associated with cognitive decline, falls, functional decline (loss of independence), excess mortality, reduced quality of life, and hospitalizations.

Thus, reducing the burden of anticholinergic and sedative medications in older adults is a key priority in the prevention of iatrogenic risk. Among the strategies developed to reduce the use of PIMs in older patients, deprescribing interventions-defined as the supervised discontinuation of inappropriate treatment-have been gradually implemented in recent years. However, few interventional studies on the deprescribing of anticholinergic and/or sedative medications have demonstrated positive results. To better understand the inconsistent effectiveness of deprescribing programs, studies have been conducted to identify the barriers and facilitators of deprescribing, and three key areas have been identified to facilitate the implementation of such programs:

  • Involve and support patients in the co-design of the intervention (participatory research) and throughout the intervention itself to reach a shared decision.
  • Work in an interdisciplinary manner by combining the areas of expertise of outpatient healthcare professionals regarding patient knowledge and support with the expertise of hospital-based professionals in the field of aging.
  • Work in a coordinated manner to foster interprofessional cooperation and ensure the transferability of the deprescribing pathway in real-world settings through multi-professional consultation.

The DIOPAS project aims to develop and implement a multidisciplinary, participatory deprescribing program for older community-dwelling patients being treated by medications with anticholinergic and/or sedative properties. The first step involves the co-development of the intervention, which is the focus of this CC-DIOPAS study. This study proposes a participatory co-development approach to the intervention, bringing together the various types of professionals (from both primary care and hospital) involved in medication optimization, as well as community-dwelling patients and patient partners.

調査の概要

研究の種類

観察的

入学 (実際)

35

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Villeurbanne、フランス、69100
        • Hôpital des Charpennes, Institut du Vieillissement

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

  • Hospital healthcare professionals involved in geriatric outpatient care and in the medication management of older patients: geriatricians, hospital pharmacists, and nurses
  • Primary care healthcare professionals involved in the medication management of the target population: general practitioners, community pharmacists, and private practice nurses
  • Patients who met the study's eligibility criteria regarding age and polypharmacy so that the co-designed intervention takes into account their needs and expectations, as well as their opinions regarding the methodology used (participative research). Partner patients will also be solicited.

説明

Inclusion Criteria:

  • Healthcare Professionals:

In hospitals:

  • Geriatricians, hospital pharmacists, or registered nurses;
  • Practicing in a geriatric day hospital at the university hospitals in Lyon, Grenoble, Marseille, Nîmes, or Nantes;
  • Agree to participate in focus group meetings or the working group.

In primary care facilities:

  • General practitioners, community pharmacists, or independent registered nurses;
  • Practicing within a primary care facility in the geographic areas served by the university hospitals of Lyon, Grenoble, Marseille, Nîmes, or Nantes;
  • Agree to participate in focus group meetings or the working group.

Patients:

Patients of the primary care facilities :

  • Patients aged 65 to 80;
  • Patients receiving outpatient care (not hospitalized) at a primary care facility within the geographic areas of the University Hospitals of Lyon;
  • Patients taking at least 5 chronic medications prescribed per day (polypharmacy);
  • Agree to participate in focus group meetings or the working group;

Partner patients:

  • Partner patients of the Lyon University Hospital or the RESHAPE laboratory;
  • Agree to participate in meetings of the working group or the study's scientific advisory board.

Exclusion Criteria:

  • None

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Healthcare professionals and patients
Health professionals and patients will be asked during focus groups and workshop on the co-developed deprescribing program

This is a qualitative study conducted in two successive phases. First, three focus groups comprising patients and healthcare professionals from both hospital and primary care settings will assess their needs, expectations, and initiatives regarding support for deprescribing, and identify the barriers and facilitators to implement a multidisciplinary pathway.

In a second phase, a multidisciplinary working group will be tasked with developing a logic model for deprescribing. This group will include hospital-based healthcare professionals, primary care professionals, and patients, with the aim of designing an intervention that is both implementable and transferable to real-world settings (2-5 workshops).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Logic model for the deprescribing pathway
時間枠:Through study completion, an average of 6 months (Following the last working group meeting)
Logic model for the community-to-hospital deprescribing pathway (DIOPAS intervention), developed by the mixed working group.
Through study completion, an average of 6 months (Following the last working group meeting)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年4月28日

一次修了 (実際)

2025年11月27日

研究の完了 (実際)

2026年1月16日

試験登録日

最初に提出

2026年6月2日

QC基準を満たした最初の提出物

2026年6月25日

最初の投稿 (実際)

2026年6月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月26日

QC基準を満たした最後の更新が送信されました

2026年6月25日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する